NEW YORK (GenomeWeb News) – The Broad Institute said today that it will use Appistry to distribute its Genome Analysis Toolkit (GATK) platform for use by for-profit companies.

Broad said that Appistry will make the GATK 2.0 platform available to for-profit companies under license agreements and subscription fees that are separate from the free arrangements used by non-profit and academic researchers. The subscription fees will cover commercial-grade support for installation, configuration, and documentation, and long-term support for each new release, Broad said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.